Mobile Health and Hybrid/Virtual Trials in Diabetes

Barry Goldstein, MD, PhD, FACE, Vice President & Therapeutic Area Head, Cardiovascular, Metabolic, Endocrinology & Renal, Covance

Dr. Barry J. Goldstein is a board-certified endocrinologist who is an internationally-recognized authority on diabetes mellitus. Dr. Goldstein has over 25 years of broad experience in clinical and basic R&D in Academia and Industry, serving as the PI or Co-PI on nearly 100 clinical trials. He is an elected member of the ASCI and AAP, a past associate editor of the two major journals in his specialty, DIABETES and the Journal of Clinical Endocrinology and Metabolism, and has served on many grant panels for NIH, ADA and JDRF as well as industry scientific advisory panels.

Dr. Goldstein received his combined MD/PhD degrees from the University of Rochester School of Medicine and Dentistry. He completed his postdoctoral research and clinical fellowships at the Joslin Diabetes Center and Brigham and Women’s Hospital, both of Harvard Medical School, where he also served on the medical faculty for several years.

Manasi Jaiman, MD, MPH, Senior Medical Director, Cardiovascular, Metabolic, Endocrinology & Renal, Covance

Dr. Manasi Jaiman has extensive clinical and academic experience in pediatric T1DM and also provides medical and scientific expertise for clinical trials and protocols in diabetes and diabetes devices. Before joining Covance, Dr. Jaiman was involved in a variety of clinical research activities including a role as a lead clinician for a major T1DM program developing a dual-chambered “bionic pancreas.”

Dr. Jaiman received an MPH in Health Systems Management from Tulane University before obtaining her MD from the Medical University of South Carolina. She completed her pediatric residency at Dartmouth-Hitchcock Medical Center and her Pediatric Endocrinology Fellowship at Massachusetts General Hospital (MGH) in Boston, Massachusetts where she continues to remain on faculty as assistant in Pediatrics.

Bola Oyegunwa, PhD, MBA, Vice President and Global Head of Hybrid and Virtual Trials, Covance

Dr. Bola Oyegunwa serves the biopharmaceutical industry as an experienced thought leader in developing and implementing innovative technology-enabled hybrid and virtual trial solutions. As a champion of reducing patient burden in clinical trials, he regularly engages with regulatory authorities across North America and Europe to remove regulatory barriers to the adoption of virtual clinical trials. Dr. Oyegunwa is an ex-strategy consultant and has held leadership roles in Corporate Strategy, Product Development and Innovation at leading CROs. He holds a PhD in Cellular Immunology & Microbiology, an MBA and MMB Professional Science Masters in Microbial Biotechnology, all from North Carolina State University.